Cannabinoid therapy cuts PTSD nightmares in a landmark trial
In a multicenter, double‑blind randomized trial, nightly dronabinol (THC) reduced PTSD‑related nightmares more than placebo over 10 weeks in 171 adults. The primary outcome (CAPS‑IV B2: nightmare frequency/intensity) favored dronabinol with a between‑group difference of −1.50 (CI −2.28 to −0.71) and a moderate effect size (Cohen’s d ≈ 0.65), supporting dronabinol as a potential pharmacotherapy for PTSD nightmares; safety was monitored during titration and maintenance, and data access is described in the publication.